Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cognitive Studies, Hospital, Neurology, Neurology |
| Therapuetic Areas: | Neurology, Psychiatry / Psychology, Other |
| Healthy: | No |
| Age Range: | 40 - 85 |
| Updated: | 1/6/2018 |
| Start Date: | January 2015 |
| End Date: | February 2018 |
Imaging [18F]AV-1451 and [18F]AV-45 in Acute and Chronic Traumatic Brain Injury
The potential long-term effects of Traumatic Brain Injury (TBI) are poorly understood.
Repeated concussions have been associated with an elevated incidence of Alzheimer's disease
(AD) along with a reduced age of onset. As repetitive TBI has been studied, a syndrome has
now been identified: chronic traumatic encephalopathy (CTE). There are growing concerns about
the long-term neurologic consequences of head impact exposure from routine participation in
contact sports (e.g., boxing, football). Brain autopsies of athletes with confirmed CTE have
demonstrated tau-immunoreactive neurofibrillary tangles and neuropil threads (known as
tauopathy). The relationship between exposure to repetitive head impact and the subsequent
development of chronic neurodegenerative disease has not been established. Further, as the
diagnosis of CTE (defined by the presence of tauopathy) is presently made after death at
autopsy, clinical tools and biomarkers for detecting it remain to be defined.
With the advent of FDA-approved PET amyloid imaging, clinicians and researchers are now able
to estimate plaque density in the brains of living patients. However, there are critical
limitations to amyloid imaging. Current evidence suggests that markers of the presence and
severity of tauopathy may be able to address these limitations. The study will utilize both
[18F] Florbetapir and [18F]-T807 PET imaging to investigate amyloid and tau accumulation in
subjects with a history of concussions. In order to determine whether problems with cognition
and memory are seen within the populations defined for the study, the researchers will
administer a core battery of neurocognitive testing. This battery will assess cognitive
abilities commonly affected by TBI, including processing speed, reaction time, new
problem-solving, executive functions, attention and concentration, and learning and memory.
These tests, in conjunction with the imaging, will be able to determine whether regional
brain activity is associated with specific cognitive problems. The researchers will obtain
PET and neurocognitive data in 3 cohorts: subjects with a history of TBIs, subjects with mild
cognitive impairment (MCI) and no TBI history, and healthy controls.
The investigators aim to determine whether individuals with TBI are on the same trajectory of
neurodegenerative disease seen in AD or in CTE. Because of the overlap in clinical/cognitive
and some behavioral symptoms in AD and CTE, an additional biomarker tool is needed to prevent
misdiagnosis. Accurate diagnosis is crucial in order to provide patients with appropriate
treatment.
Repeated concussions have been associated with an elevated incidence of Alzheimer's disease
(AD) along with a reduced age of onset. As repetitive TBI has been studied, a syndrome has
now been identified: chronic traumatic encephalopathy (CTE). There are growing concerns about
the long-term neurologic consequences of head impact exposure from routine participation in
contact sports (e.g., boxing, football). Brain autopsies of athletes with confirmed CTE have
demonstrated tau-immunoreactive neurofibrillary tangles and neuropil threads (known as
tauopathy). The relationship between exposure to repetitive head impact and the subsequent
development of chronic neurodegenerative disease has not been established. Further, as the
diagnosis of CTE (defined by the presence of tauopathy) is presently made after death at
autopsy, clinical tools and biomarkers for detecting it remain to be defined.
With the advent of FDA-approved PET amyloid imaging, clinicians and researchers are now able
to estimate plaque density in the brains of living patients. However, there are critical
limitations to amyloid imaging. Current evidence suggests that markers of the presence and
severity of tauopathy may be able to address these limitations. The study will utilize both
[18F] Florbetapir and [18F]-T807 PET imaging to investigate amyloid and tau accumulation in
subjects with a history of concussions. In order to determine whether problems with cognition
and memory are seen within the populations defined for the study, the researchers will
administer a core battery of neurocognitive testing. This battery will assess cognitive
abilities commonly affected by TBI, including processing speed, reaction time, new
problem-solving, executive functions, attention and concentration, and learning and memory.
These tests, in conjunction with the imaging, will be able to determine whether regional
brain activity is associated with specific cognitive problems. The researchers will obtain
PET and neurocognitive data in 3 cohorts: subjects with a history of TBIs, subjects with mild
cognitive impairment (MCI) and no TBI history, and healthy controls.
The investigators aim to determine whether individuals with TBI are on the same trajectory of
neurodegenerative disease seen in AD or in CTE. Because of the overlap in clinical/cognitive
and some behavioral symptoms in AD and CTE, an additional biomarker tool is needed to prevent
misdiagnosis. Accurate diagnosis is crucial in order to provide patients with appropriate
treatment.
The study involves two days of study visits. Subjects will be given a copy of the consent
form on the morning of their first visit, and sign consent in a private room at Mount Sinai
before any research related procedures are conducted. Subjects will then be brought to the
Hess Center for Science in Medicine for injection for the [18F] AV-45 (or Amyvid) PET scan.
On the second visit, which is to be conducted the day after the first visit, subjects will
have the [18F]AV-1451 (or T807) PET scan and complete the neuropsychological testing battery.
Both PET scans will be done entirely for the purpose of research. The scans will be read by
nuclear medicine physicians and a clinical report will be sent to the PI. Any clinically
relevant findings will be sent to the treating physician and will be communicated to
patients. During both visits, subjects will be allowed time for meals and breaks between
study procedures.
Details of procedures:
Amyvid PET scan: At the first visit, each participant will have an Amyvid PET scan. The scan
involves use of a "tracer", which is a radioactive sugar-like substance. This type of PET
scan involves a tracer called AV-45 (also known as Florbetapir, and by the trade name of
Amyvid). It has been approved by the FDA for use in PET imaging. It binds to beta-Amyloid
plaques that may or may not be present in the brain. Amyloid plaque is a sticky substance
(protein) that accumulates in the brain in larger amounts in people who may have Alzheimer's
disease. A thin line will be inserted into a vein in one arm for the injection of the tracer.
Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and
scanned for about 20 minutes.
T807 PET scan: On the day of the second visit, each participant will have an [F18] AV-1451
PET scan, also known as a T807 PET scan. This type of PET scan is being studied by the FDA as
a diagnostic tool. This PET scan involves a very similar procedure to the Amyvid PET scan the
day before. Like the Amyvid scan, a thin line will be inserted into a vein in one arm for the
injection of the AV-1451 radiotracer. This tracer binds to clusters of Tau protein inside the
brain called neurofibrillary tangles. These tangles are associated with both Alzheimer's
disease and memory problems that may be related to multiple head injuries or concussions.
Scanning will begin 80 minutes after the injection of the tracer, and last for about 20
minutes.
Neuropsychological testing battery: The neuropsychological assessment is a battery of pencil
and paper tests that measure memory and thinking abilities. In total it takes about two hours
to complete.
form on the morning of their first visit, and sign consent in a private room at Mount Sinai
before any research related procedures are conducted. Subjects will then be brought to the
Hess Center for Science in Medicine for injection for the [18F] AV-45 (or Amyvid) PET scan.
On the second visit, which is to be conducted the day after the first visit, subjects will
have the [18F]AV-1451 (or T807) PET scan and complete the neuropsychological testing battery.
Both PET scans will be done entirely for the purpose of research. The scans will be read by
nuclear medicine physicians and a clinical report will be sent to the PI. Any clinically
relevant findings will be sent to the treating physician and will be communicated to
patients. During both visits, subjects will be allowed time for meals and breaks between
study procedures.
Details of procedures:
Amyvid PET scan: At the first visit, each participant will have an Amyvid PET scan. The scan
involves use of a "tracer", which is a radioactive sugar-like substance. This type of PET
scan involves a tracer called AV-45 (also known as Florbetapir, and by the trade name of
Amyvid). It has been approved by the FDA for use in PET imaging. It binds to beta-Amyloid
plaques that may or may not be present in the brain. Amyloid plaque is a sticky substance
(protein) that accumulates in the brain in larger amounts in people who may have Alzheimer's
disease. A thin line will be inserted into a vein in one arm for the injection of the tracer.
Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and
scanned for about 20 minutes.
T807 PET scan: On the day of the second visit, each participant will have an [F18] AV-1451
PET scan, also known as a T807 PET scan. This type of PET scan is being studied by the FDA as
a diagnostic tool. This PET scan involves a very similar procedure to the Amyvid PET scan the
day before. Like the Amyvid scan, a thin line will be inserted into a vein in one arm for the
injection of the AV-1451 radiotracer. This tracer binds to clusters of Tau protein inside the
brain called neurofibrillary tangles. These tangles are associated with both Alzheimer's
disease and memory problems that may be related to multiple head injuries or concussions.
Scanning will begin 80 minutes after the injection of the tracer, and last for about 20
minutes.
Neuropsychological testing battery: The neuropsychological assessment is a battery of pencil
and paper tests that measure memory and thinking abilities. In total it takes about two hours
to complete.
Inclusion Criteria:
- males between 40 to 85 years of age
- individuals who participated in contact sports (e.g., active and retired NFL players,
NHL players, boxers, NCAA athletes) and other individuals (including but not limited
to veterans, breachers, or law enforcement officials with multiple blast exposures)
who all have a history of one or more concussions and have a memory or cognitive
complaint
- individuals with Mild Cognitive Impairment (MCI) and no history of concussion or TBI
- healthy controls with no history of head injury and no current cognitive or memory
problems
- all participants require a study partner, who is well acquainted with the participant,
to answer questions either in person or over the telephone about the individuals'
activities of daily living, and to corroborate cognitive problems and past history of
brain injury
Exclusion Criteria:
- any significant neurological disease, such as Alzheimer's disease, Parkinson's
disease, vascular dementia, Huntington's disease, Pick's disease, Lewy Body Dementia,
frontotemporal dementia, normal pressure hydrocephalus, brain tumor, progressive
supranuclear palsy, seizure disorder, or multiple sclerosis
- any significant systemic illness or unstable medical condition, including:
uncontrolled diabetes mellitus, uncorrected hypothyroidism or hyperthyroidism, or
systemic cancer
- a history of schizophrenia or psychosis, alcohol or substance abuse or dependence
within the past 6 months
- clinically significant impairment of liver or renal function
- significant cerebrovascular disease
- impairment of visual or auditory acuity sufficient to interfere with completion of
study procedures
- education level < 10 years
- any subjects with a history of risk factors for Torsades de Pointes, or subjects
taking drugs known to prolong the QT interval
- subjects who have had 2 or more PET scans within the past year, or other significant
exposure to radiation (i.e., radiation therapy)
We found this trial at
1
site
1428 Madison Ave
New York, New York 10029
New York, New York 10029
(212) 241-6500
Principal Investigator: Sam Gandy, MD, PhD
Phone: 212-241-5290
Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai is...
Click here to add this to my saved trials
